Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.
Hatice Güngör(Ovarian Cancer Action), Hani Gabra(Royal Children's Hospital), Emily Pickford(Ovarian Cancer Action), Nona Rama(Ovarian Cancer Action), Ms. Xue Yu Chen, Azeem Saleem, S. C. Carme, Yuet Lewis, Elizabeth C. Krachey(Research Triangle Park Foundation), Roshan Agarwal(Imperial College Healthcare NHS Trust), Roger N. Gunn(GlaxoSmithKline (United Kingdom)), Sarah P. Blagden(Churchill Hospital), Mona El‐Bahrawy(Al-Azhar University), Euan A. Stronach(Age UK), Agnieszka Michael(University of Surrey), Ademi Santiago-Walker, Shannon R. Morris(Research Triangle Park Foundation), Cristian Salinas(Hammersmith Hospital), Syed Babar, Deborah A. Smith(Research Triangle Park Foundation)
Cited by 14
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222